Posted by Michael Wonder on 12 Jan 2018
Pharma collaborates to improve chances of NICE backing Duchenne drugs
11 January 2018 - A group of pharma companies and Duchenne UK are collaborating to improve the chances of new treatments for Duchenne muscular dystrophy gaining NICE approval.
Roche, Pfizer, PTC Therapeutics, and Sarepta are sponsoring the project focused on drugs for Duchenne muscular dystrophy, led by the charity Duchenne UK.
The HERCULES project aims to help share best practice on generating clinical trial data and quality of life data, so that chances of any drug gaining a positive decision from NICE is increased.
